SCHEDULE: Tang Capital Reports 4.997% Stake in Elevation Oncology

Tang Capital Management and affiliates report a 4.997% beneficial ownership stake in Elevation Oncology, Inc., primarily through exercisable warrants.

Summary

• Tang Capital Management, LLC, Kevin Tang, and Tang Capital Partners, LP collectively report beneficial ownership of 3,115,000 shares of Elevation Oncology, Inc. common stock.
• This represents 4.997% of the Issuer's outstanding common stock.
• All reported shares are currently issuable upon the exercise of warrants.
• The percentage calculation is based on 62,338,729 shares of common stock outstanding, which includes 59,223,729 shares as of May 9, 2025, and the 3,115,000 shares from warrants.
• The reporting persons share both voting and dispositive power over these shares.
• A limitation exists where Tang Capital Partners, LP cannot exercise warrants if it would result in owning more than 9.99% of the Issuer's outstanding shares.

Sentiment

Score: 6

Explanation: The filing is a routine beneficial ownership disclosure, indicating a significant investor maintains a stake, which can be viewed as a neutral to slightly positive signal of continued interest, but provides no operational or financial performance updates.

Positives

• A significant institutional investor, Tang Capital, maintains a substantial beneficial ownership stake in Elevation Oncology, indicating continued interest.
• The shares are held via warrants, suggesting a potential future capital inflow to the company upon exercise, though subject to ownership limitations.

Negatives

• The beneficial ownership percentage of 4.997% is just below the 5% threshold that would typically trigger more detailed disclosure (Schedule 13D) if the intent was to influence control, suggesting a passive investment strategy.

Risks

• Tang Capital Partners, LP is restricted from exercising warrants if it would result in their beneficial ownership exceeding 9.99% of Elevation Oncology's outstanding common stock.

Future Outlook

The 3,115,000 shares are currently issuable upon exercise of warrants, which expire five years from their issuance date. Tang Capital Partners, LP is subject to a 9.99% ownership limitation upon warrant exercise.

Industry Context

This filing reflects a passive investment stake by a specialized capital management firm in a biotechnology company, a common occurrence in the sector where early-stage companies often rely on institutional funding and strategic investments.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, potentially influencing market perception.
• Company (Elevation Oncology): Potential for future capital infusion if warrants are exercised, subject to ownership limitations.

Next Steps

• Continued holding of warrants by Tang Capital Partners, LP, which are immediately exercisable and expire five years from issuance.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by a passive investor group. It does not contain information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The continued holding of a significant stake by Tang Capital suggests ongoing investor interest, but without further fundamental data, a 'hold' recommendation is appropriate for existing investors.

Keywords

Elevation Oncology, Common Stock, Warrants, Beneficial Ownership, Schedule 13G, Tang Capital Management, Biotechnology, Oncology